Merck invests ⬠250M in new biotech development centre in Switzerland
Merck invests ⬠250M in new biotech development centre in Switzerland 07 July 2021 | News
image credit- businesswire
German firm Merck has announced the topping-out ceremony for its new Biotech Development Center in Corsier-sur-Vevey, Switzerland.
This investment of € 250 million, which was announced in January 2020, is intended to help secure the capacities for a cost-efficient and agile provision of clinical study medication in the long term, to shorten the development time of novel biological active ingredients and to meet the challenge of the increasingly complex production of biotechnological substances to master the next generation.
Merck Celebrates Key Milestone in Construction of Biotech Development Center in Switzerland finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced changes in its operating model for the Healthcare business sector. Chris Round will become President of EMD Serono leading the North America Healthcare business; Andrew Paterson will assume the position of Chief Marketing Officer; and recruitment is ongoing for the position of Head of China & International.
“Our redesigned Healthcare organization creates dedicated leadership for our strategic priorities with a focus on growth,” said Peter Guenter, Member of the Executive Board of Merck KGaA, Darmstadt, Germany, and CEO Healthcare. “Our clear intent is to bring meaningful value to more patients with our current and future portfolio.”
May 18, 2021 11:39am
Germany-based Merck KGaA saw an 8.6% increase in sales in 2020 and looks for even more success with reorganization of its healthcare unit in North America as it tries to spur sales of Mavenclad, Bavencio and Tepmetko. (Fierce Pharma)
Belen Garijo took over last month as CEO at Merck KGaA and she’s not wasting time putting her imprint on the company.
On Tuesday, the Germany-based company said it had tapped Chris Round as president at its North America healthcare unit, replacing Andrew Patterson, who ll step into the brand-new role of chief marketing officer.
By beefing up its leadership in the United States, Merck aims to help EMD Serono cash in with three promising drugs––its Pfizer-partnered immuno-oncology drug Bavencio, multiple sclerosis treatment Mavenclad and Tepmetko for non-small cell lung cancer.